ClinicalTrials.gg
TerminatedNCT02051218Updated Oct 23, 2026

Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

A Phase 3 interventional study of Denosumab (reduced dosing) and Denosumab (standard dosing) in Metastatic Breast Cancer, Metastatic Prostate Cancer and Bone Metastases, sponsored by Swiss Cancer Institute. Terminated at 50 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Swiss Cancer Institute · Phase 3, Interventional, and Supportive care

How we know

Why this study was terminated
Board decision as by March 2026, the number of patients undergoing treatment decreased to around 50, from the total 1,380 patients enrolled in the trial. And due to price changes in medication
Updated Oct 23, 2026Now TerminatedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,380
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies testing denosumab in Breast Neoplasms — none open to participants now, 3 under way, 2 of them phase 3. Denosumab · Breast Neoplasms.

Enrollment
4th of 24
1,380 · median 53
Started
2014
the only one that year
Phase 3
9 of 24
none open now
Registered
11th of 24
by date

Among the 24 studies testing denosumab in Breast Neoplasms, this one is the 4th largest by enrollment, is the only one that started in 2014, is one of 9 in phase 3, and was the 11th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

None of the 24 studies testing denosumab in Breast Neoplasms is open now. The open studies under Breast Neoplasms, anywhere →

About denosumab

Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 24 studies testing denosumab in Breast Neoplasms as a file.
02

Study summary

The aim of the trial is to test the hypothesis that the benefit of denosumab is maintained if administered only every 12 weeks as compared to every 4 weeks.

Read the detailed description

Denosumab, a monoclonal antibody against RANK-Ligand has been shown superior to zoledronic acid in delaying time to a first on-study skeletal related event (SRE) in patients with solid tumors, with no effects on disease progression or survival. Many SREs were silent compression fractures found only because of scheduled imaging. The approved dose of denosumab is 120 mg s.c. every 4 weeks (q4w). Although generally well tolerated, there is a time-dependent increase in osteonecrosis of the jaw in up to 8% of patients. Cases of fatal hypocalcaemia were observed during post marketing surveillance.

The optimal dose and schedule for denosumab is unknown. Denosumab is associated with considerable costs and may add toxicity; thus a study of de-escalation is warranted.

The aim of the trial is to test the hypothesis that the benefit of Denosumab is maintained if administered 120 mg q12w as compared to 120 mg q4w. The primary endpoint of this open-label randomized phase III non-inferiority trial is time to first on-trial symptomatic skeletal event (SSE: i.e. clinically significant pathological fracture, radiation therapy to bone, surgery to bone or spinal cord compression). With a non-inferiority margin of 1.2 for the hazard ratio, a power 80% and a type I error 5%, the total sample size is 1380. Secondary endpoints are safety, time to subsequent on-trial SSE, quality of life, health economic outcomes, and change in bone turnover markers. This study is open for international collaboration.

03

Conditions studied

  • Metastatic Breast Cancer
  • Metastatic Prostate Cancer
  • Bone Metastases

Keywords

  • metastatic breast cancer
  • castration resistant metastatic prostate cancer
  • bone metastases
  • Denosumab
  • XGEVA
  • de-escalation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient has given written .
  • confirmed diagnosis of breast or prostate cancer before randomization.
  • Patient has breast cancer (stage IV, all subtypes allowed) or prostate cancer (stage IV) and bone metastases and is planned to receive or is receiving antineoplastic treatment.
  • Patients with prostate cancer must have evidence of disease progression on continuous androgen deprivation therapy (CRPC).
  • Patients must have ≥ 3 bone metastases (lytic or blastic or mixed). The lesions must be documented by radiological evaluation within 12 weeks before randomization (by X-Ray, CT scan, PET-CT, MRI scan or bone scintigraphy).
  • 0-2
  • Age ≥ 18 years.
  • Corrected serum calcium ≥ 2 mmol/l and ≤ 3 mmol/l (medical treatments to obtain serum calcium levels in the normal range are allowed, as far as no denosumab is used. Maximally 1 dose of bisphosphonates in the case of hypercalcemia is allowed, if the bisphosphonate was applied at least 3 weeks before the first dose of denosumab).
  • Liver transaminases not more than 1.5 x or not more than 3 x ULN with liver metastases. Serum total ≤ 1.5 x ULN (≤ 2.0 x ULN in case of known Gilbert's disease)
  • Women are not breastfeeding. Women with are using effective , are not pregnant and agree not to become pregnant during participation in the trial and during the 12 months thereafter. A negative pregnancy test before inclusion (within 7 days) into the trial is required for all women with child-bearing potential.
  • Men agree not to father a child during participation in the trial and during 12 months thereafter.

Exclusion criteria

Exclusion Criteria:

  • Definite for denosumab (e.g. hypocalcaemia [Albumin-corrected serum calcium \< 2.0 mmol/l]).
  • History or current evidence of osteonecrosis of the jaw.
  • Non-healed mucosa in oral cavity (by surgery or as a side effect of any other treatment).
  • Jaw or dental conditions that require oral surgery or if surgery or invasive dental procedures are planned.
  • Prior use of denosumab for bone (dose 120 mg every 4 weeks) or bisphosphonates to treat bone metastases. Patients treated with denosumab or bisphosphonates against osteopenia or osteoporosis are allowed to enter the trial if the last dose was more than 28 days before randomization.
  • Patients with known osteoporosis (T-score ≤ -2.5) at study entry (since fractures from osteoporosis are difficult to be discriminated from fractures through bone metastases).
  • Radiotherapy or surgery to the bone within the last two weeks before randomization or planned within 6 weeks after randomization.
  • Presence or history of or . A MRI evaluation within 12 weeks before randomization must be performed in case of suspicious symptoms.
  • Psychiatric disorder precluding understanding of information on trial related topics, giving , filling out QoL forms.
  • Concurrent treatment in a clinical trial with SSE or SRE as primary endpoint.
  • Known to trial drug or hypersensitivity to any other component of the trial drug (e.g. fructose).
  • Any concomitant drugs contraindicated for use with the trial drugs according to the approved product information.
  • Any psychological, familial, sociological or geographical condition potentially hampering compliance with the trial protocol.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,380 participants (actual)

Study arms

  • Active comparator
    Arm A (standard arm)

    Denosumab 120mg (XGEVA®) sc. q4w

    Drug: Denosumab (standard dosing)

  • Experimental
    Arm B (reduced arm)

    Denosumab 120mg (XGEVA®) sc. q4w \[weeks 1, 5, 9\] followed by Denosumab 120mg (XGEVA®) sc. q12w \[weeks 13, 25, …\]

    Drug: Denosumab (reduced dosing)

Interventions

  • DrugDenosumabStudies of DenosumabDenosumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    3x Denosumab 120mg (XGEVA®) sc. q4w followed by Denosumab 120mg (XGEVA®) sc. q12w

    Also known as: XGEVA®

  • DrugDenosumabStudies of DenosumabDenosumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Denosumab 120mg (XGEVA®) sc. q4w

    Also known as: XGEVA®

06

What researchers measure

Primary outcomes

  1. Time to first on-trial symptomatic skeletal event (SSE; Clinically significant pathological fracture, radiation therapy to bone, surgery to bone or spinal cord compression).

    A SSE is defined as one of the following events: Clinically significant pathological fracture, radiation therapy to bone, surgery to bone, or spinal cord compression.

    Time frame: at the latest 5 years after randomization.

Secondary outcomes

  1. Toxicity (focus on hypocalcaemia and osteonecrosis of the jaw)

    Time frame: at the latest 5 years after randomization.

  2. Time to first and subsequent on-trial SSE

    Time frame: at the latest 5 years after randomization.

  3. Quality of Life measured by FACT-G and FACT-BP

    Time frame: at the latest 5 years after randomization.

  4. Skeletal morbidity period rate (SMPR)

    Time frame: at the latest 5 years after randomization.

  5. Skeletal morbidity rate (SMR)

    Time frame: at the latest 5 years after randomization.

  6. Health economic analysis

    Time frame: at the latest 5 years after randomization.

  7. Bone turnover markers

    Time frame: at the latest 5 years after randomization.

  8. Overall Survival (OS)

    Time frame: at the latest 5 years after randomization.

07

Study locations

50 sites
  • Landeskrankenhaus Feldkirch
    Feldkirch, 6800, Austria
  • Klinikum Wels-Grieskrichen GmbH
    Wels, 4600, Austria
  • Uniklinik Düsseldorf, Urologische Klinik
    Düsseldorf, 40225, Germany
  • Universitätsklinikum Düsseldorf, Frauenheilkunde/Geburtshilfe
    Düsseldorf, 40225, Germany
  • Universitätsmedizin Göttingen
    Göttingen, 37075, Germany
  • Universitätsklinikum Schleswig-Holstein
    Lübeck, 23538, Germany
  • Universitäts-Frauenklinik Ulm
    Ulm, 89075, Germany
  • Brustzentrum-Zürich
    Zurich, Canton of Zurich 8005, Switzerland
  • Klinik für Hämatologie und Onkologie Hirslanden Zürich AG
    Zurich, Canton of Zurich 8032, Switzerland
  • Universitätsspital Zürich
    Zurich, Canton of Zurich 8091, Switzerland
  • Stadtspital Zürich Triemli
    Zurich, Canton of Zurich CH-8063, Switzerland
  • Hôpital du Valais Sion
    Sion, Sion 1951, Switzerland
  • Hirslanden Klinik Aarau
    Aarau, CH-5001, Switzerland
  • Kantonspital Aarau
    Aarau, CH-5001, Switzerland
  • Kantonsspital Baden
    Baden, CH-5404, Switzerland
  • Universitaetsspital Basel
    Basel, 4031, Switzerland
  • Brustzentrum Basel - Praxis für ambulante Tumortherapie
    Basel, 4052, Switzerland
  • St. Claraspital AG
    Basel, CH-4016, Switzerland
  • Istituto Oncologico della Svizzera Italiana - Ospedale Regionale Bellinzona e Valli
    Bellinzona, 6500, Switzerland
  • Klinik Engeried / Praxis Oncocare
    Bern, 3012, Switzerland
  • Inselspital, Bern
    Bern, CH-3010, Switzerland
  • Spitalzentrum Biel
    Biel, CH-2501, Switzerland
  • Spitalzentrum Oberwallis
    Brig, 3900, Switzerland
  • Centre du Sein de Genève, Clinique des Grangettes
    Chêne-Bougeries, 1224, Switzerland
  • Kantonsspital Graubünden
    Chur, 7000, Switzerland
  • Kantonsspital Frauenfeld - Brustzentrum
    Frauenfeld, 8501, Switzerland
  • Hopital Fribourgeois
    Fribourg, 1708, Switzerland
  • Hopitaux Universitaires de Geneve
    Geneva, 1211, Switzerland
  • Clinique De Genolier
    Genolier, 1272, Switzerland
  • Hôpital neuchâtelois
    La Chaux-de-Fonds, 2300, Switzerland
  • CCAC Lausanne
    Lausanne, 1004, Switzerland
  • CHUV
    Lausanne, 1011, Switzerland
  • Kantonsspital Liestal
    Liestal, CH-4410, Switzerland
  • Fondazione Oncologia / Oncologia ematologia
    Locarno, 6600, Switzerland
  • Luzerner Kantonsspital
    Lucerne, 6000, Switzerland
  • Hirslanden Klinik St. Anna Luzern
    Lucerne, 6006, Switzerland
  • Oncologia Varini & Calderoni & Christinat
    Lugano, 6900, Switzerland
  • Onkologie Zentrum Spital Männedorf
    Männedorf, 8708, Switzerland
  • Kantonsspital Muensterlingen
    Münsterlingen, 8596, Switzerland
  • Kantonsspital Olten
    Olten, 4600, Switzerland
  • Tumor and Brustzentrum Ostschweiz TBZO
    Sankt Gallen, 9016, Switzerland
  • Tumor and Brustzentrum Ostschweiz TBZO
    Sankt Gallen, CH-9006, Switzerland
  • Kantonsspital St. Gallen
    Sankt Gallen, CH-9007, Switzerland
  • Rundum Onkologie am Bahnhofpark
    Sargans, 7320, Switzerland
  • Spital Limmattal
    Schlieren, 8952, Switzerland
  • Bürgerspital Solothurn - Zentrum für Onkologie und Hämatologie
    Solothurn, 4500, Switzerland
  • Spital STS AG
    Thun, 3600, Switzerland
  • Kantonsspital Winterthur
    Winterthur, 8401, Switzerland
  • Onkologie Bellevue
    Zurich, 8001, Switzerland
  • Onkozentrum Klinik im Park
    Zurich, 8038, Switzerland
08

References and documents

Publications

  • Adams A, Jakob T, Huth A, Monsef I, Ernst M, Kopp M, Caro-Valenzuela J, Wockel A, Skoetz N. Bone-modifying agents for reducing bone loss in women with early and locally advanced breast cancer: a network meta-analysis. Cochrane Database Syst Rev. 2024 Jul 9;7(7):CD013451. doi: 10.1002/14651858.CD013451.pub2. PubMed 38979716 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jul 2014 to primary completion in Mar 2026, 140 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Jun 2026 → Mar 2026 and completion Dec 2028 → Mar 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2014
First posted
Jan 31, 2014
StartActual
Jul 16, 2014
Primary completionActual
Mar 20, 2026was Jun 2026
CompletionActual
Mar 20, 2026was Dec 2028
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Terminated Board decision as by March 2026, the number of patients undergoing treatment decreased to around 50, from the total 1,380 patients enrolled in the trial. And due to price changes in medication
changed Oct 23, 2026
Sites
5 sites added, 5 sites removed
Show 5 added (5 Switzerland)
  • Brustzentrum-Zürich · Zurich, Switzerland
  • Klinik für Hämatologie und Onkologie Hirslanden Zürich AG · Zurich, Switzerland
  • Universitätsspital Zürich · Zurich, Switzerland
  • Stadtspital Zürich Triemli · Zurich, Switzerland
  • Hôpital du Valais Sion · Sion, Switzerland
Show 5 removed
  • Hôpital du Valais Sion · Sion, Switzerland
  • Brustzentrum-Zürich · Zurich, Switzerland
  • Klinik für Hämatologie und Onkologie Hirslanden Zürich AG · Zurich, Switzerland
  • Universitätsspital Zürich · Zurich, Switzerland
  • Stadtspital Zürich Triemli · Zurich, Switzerland
Oct 23, 2026
Primary completion
Jun 30, 2026→Mar 20, 2026 (actual)
Oct 23, 2026
Study completion
Dec 31, 2028→Mar 20, 2026 (actual)
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Active, not recruiting→Terminated
    Why stopped Board decision as by March 2026, the number of patients undergoing treatment decreased to around 50, from the total 1,380 patients enrolled in the trial. And due to price changes in medication
    5 sites added, 5 sites removed
    Show 5 added (5 Switzerland)
    • Brustzentrum-Zürich · Zurich, Switzerland
    • Klinik für Hämatologie und Onkologie Hirslanden Zürich AG · Zurich, Switzerland
    • Universitätsspital Zürich · Zurich, Switzerland
    • Stadtspital Zürich Triemli · Zurich, Switzerland
    • Hôpital du Valais Sion · Sion, Switzerland
    Show 5 removed
    • Hôpital du Valais Sion · Sion, Switzerland
    • Brustzentrum-Zürich · Zurich, Switzerland
    • Klinik für Hämatologie und Onkologie Hirslanden Zürich AG · Zurich, Switzerland
    • Universitätsspital Zürich · Zurich, Switzerland
    • Stadtspital Zürich Triemli · Zurich, Switzerland
    Primary completion Jun 30, 2026→Mar 20, 2026 (now actual)
    Study completion Dec 31, 2028→Mar 20, 2026 (now actual)
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02051218
Lead sponsor
Swiss Cancer Institute
Responsible party
Sponsor
First posted
Jan 31, 2014
Start date
Jul 16, 2014
Primary completion
Mar 20, 2026
Completion
Mar 20, 2026
Last update
Oct 23, 2026

Study contacts

Roger von Moos, PD MD
study chair · Kantonsspital Graubünden
Arnoud Templeton, MD
study chair · Cantonal Hospital of St. Gallen
Silke Gillessen, Prof
study chair · Cantonal Hospital of St. Gallen
Andreas Müller, MD
study chair · Kantonsspital Winterthur KSW

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion